Saturday 17 October 2026
Export ADTX’s income statement to Excel — free account
Aditxt, Inc.
ADTX Healthcare Biotechnology
Aditxt, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3,200.00, down 97.6% from fiscal 2024. In the quarter to March 2026, revenue grew 1,120.0%, EPS grew 99.6% and free cash flow grew 60.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.00
0.00
NaN
Follow ADTX
| Older periods | Jun '25 | Sep '25 | Dec '25 | Mar '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
4 | — | — | — |
| (338.55%) | 1,915.52% | (1,708.64%) | 549.59% | ||
| (101.67%) | (202.88%) | (177.15%) | (236.38%) | ||
ROIC |
(118.41%) | 0.00% | (1,619.88%) | 0.00% | |
Return on Tangible Assets |
165.67% | 223.57% | 573.29% | 456.62% | |
Average Days of Receivables |
1,197.56 | 11,642.88 | 0.00 | 306.29 | |
Free Cash Flow per Share |
(226,094.00) | (112,948.50) | (18,365.36) | (920.15) | |
Free Cash Flow |
(22.61) | (22.59) | (25.71) | (18.59) | |
Capital Expenditures |
— | — | (0.02) | (0.03) | |
| Other line items | |||||
Cash ROIC |
(183.54%) | 259.77% | (359.49%) | 53.25% | |
Accounts Receivable Turnover |
0.05 | 0.01 | 0.00 | 0.02 | |
Accounts Payable Turnover |
0.05 | 0.01 | 0.00 | 0.00 | |
Inventory Turnover |
1.89 | 1.54 | 0.34 | 0.17 | |
Average Days of Payables |
7,202.84 | 57,475.57 | 968,307.24 | 251,304.09 | |
Days of Inventory on Hand |
5.14 | 32.82 | 730.00 | 4,075.30 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
26,124.79% | 56,635.59% | 103,035.48% | 21,202.80% | |
Selling, General and Administrative Expense of Revenue |
152,259.50% | 290,562.71% | 528,287.10% | 106,960.14% | |
Share Based Compensation of Revenue |
4,030.58% | 8,264.41% | 15,590.32% | 3,309.79% | |
Interest Coverage |
(27.20) | (49.00) | (28.73) | (33.27) | |
Operating CF/Net income |
0.73 | 0.53 | 0.60 | 0.35 | |
Depreciation/Fixed assets |
2.65 | 1.55 | 2.00 | 1.93 | |
Capex/Depreciation |
0.00 | 0.00 | (0.01) | (0.02) | |
Revenue per Share |
121.00 | 29.50 | 2.21 | 0.71 | |
Operating CF per Share |
(226,094.00) | (112,948.50) | (18,348.86) | (918.50) | |
Capex per Share |
0.00 | 0.00 | (16.50) | (1.65) | |
Capex to Sales |
0.00 | 0.00 | 7.45 | 2.34 |
Columns are period end dates · fundamentals updated 2 Oct 2026